An international Prospective, Open-label, Multi-Center, Randomized Phase III Study comparing lutetium (177LU) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (PSMA DC 2302)
The purpose of this study is to evaluate the efficacy of AAA617 versus observation after Stereotactic Body Radiation Therapy (SBRT), in delaying castration or disease recurrence in adult patients with PSMA positive OMPC with 1 to 5 metastatic lesions detected by PSMA PET using gallium (68Ga) gozetotide or piflufolastat (18F), negative for M1 disease by conventional imaging (CI).
Principal Investigator: Dr. Medhat Osman
Study Coordinators: Lindsey Vargo and Brittany Minor
This study is currently enrolling patients. To learn more about PSMA DC 2302 and how you can join contact our research office at (314) 289-7690
This study is funded by the Foundation through Novartis
Principal Investigator: Dr. Medhat Osman
Study Coordinators: Lindsey Vargo and Brittany Minor
This study is currently enrolling patients. To learn more about PSMA DC 2302 and how you can join contact our research office at (314) 289-7690
This study is funded by the Foundation through Novartis